REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $33.45.

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of REGENXBIO in a research note on Wednesday, January 15th. StockNews.com cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, February 15th. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Morgan Stanley reissued an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th.

REGENXBIO Price Performance

RGNX opened at $6.93 on Tuesday. The firm has a market capitalization of $343.35 million, a price-to-earnings ratio of -1.38 and a beta of 1.29. The company’s 50 day simple moving average is $7.67 and its two-hundred day simple moving average is $9.56. REGENXBIO has a 1-year low of $6.56 and a 1-year high of $28.80.

Institutional Trading of REGENXBIO

Several institutional investors have recently added to or reduced their stakes in RGNX. Barclays PLC boosted its position in shares of REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock worth $1,217,000 after buying an additional 67,948 shares during the period. Assenagon Asset Management S.A. lifted its stake in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after acquiring an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 17,533 shares during the period. FMR LLC grew its position in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares in the last quarter. Finally, Stifel Financial Corp increased its stake in REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after purchasing an additional 17,563 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.